PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.68M (Avg.)
18.02 | 2.27
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-15.69%
Negative net income growth while CRK stands at 9.32%. Joel Greenblatt would see a comparative disadvantage in bottom-line performance.
0.13%
Less D&A growth vs. CRK's 328.52%, reducing the hit to reported earnings. David Dodd would confirm that core assets remain sufficient.
275.64%
Well above CRK's 218.89% if it’s a large positive yoy. Michael Burry would see a bigger future tax burden vs. competitor’s approach.
No Data
No Data available this quarter, please select a different quarter.
-328.54%
Negative yoy working capital usage while CRK is 252.65%. Joel Greenblatt would see more free cash if revenue remains unaffected, giving a short-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-328.54%
Negative yoy usage while CRK is 0.00%. Joel Greenblatt would see a short-term advantage in freeing up capital unless competitor invests effectively in these lines.
224.19%
Lower 'other non-cash' growth vs. CRK's 1296.89%, indicating steadier reported figures. David Dodd would confirm no missed necessary write-downs or gains.
-28.82%
Negative yoy CFO while CRK is 364.60%. Joel Greenblatt would see a disadvantage in operational cash generation vs. competitor.
21.91%
Some CapEx rise while CRK is negative at -602.88%. John Neff would see competitor possibly building capacity while we hold back expansions.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Liquidation growth of 100.00% while CRK is zero at 0.00%. Bruce Berkowitz sees a mild difference in monetizing portfolio items that must be justified by market valuations.
-85.51%
We reduce yoy other investing while CRK is 0.00%. Joel Greenblatt sees a near-term cash advantage unless competitor’s intangible or side bets produce strong returns.
-458.90%
Both yoy lines negative, with CRK at -602.88%. Martin Whitman suspects a broader cyclical shift away from heavy investing across the niche.
-294.84%
We cut debt repayment yoy while CRK is 0.00%. Joel Greenblatt sees competitor possibly lowering risk more if expansions do not hamper them.
-20.41%
Both yoy lines negative, with CRK at -99.14%. Martin Whitman suspects an environment or preference for internal financing over new equity in the niche.
17.81%
Buyback growth of 17.81% while CRK is zero at 0.00%. Bruce Berkowitz sees a modest per-share advantage that might accumulate if the stock is below intrinsic value.